From therapeutic antibodies to immune complex vaccines

Wang, Xuanyi; Wang, Bin; Wen, Yiping

doi:10.1038/s41541-018-0095-z

Cited by 48 publications

(57 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies point to a role for ICs in enhancing antigen uptake and presentation by dendritic cells (DCs) via FcγRs binding. DCs are in turn strongly activated and drive enhanced immune responses [9,10]. In agreement with this, DCs activated in vitro with antibodyopsonized SIV virions improved antiviral T-cell responses.…”

Section: Mechanisms Involved In the Enhancement Of Adaptive Immune Rementioning

confidence: 53%

See 1 more Smart Citation

Vaccinal effect of HIV-1 antibody therapy

Naranjo-Gómez¹,

Pelegrin²

2019

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

This review recalls recent findings regarding the induction of vaccinal effects by HIV-1 broadly neutralizing antibodies (bNAbs) and highlights potential therapeutic strategies to exploit such immunomodulatory properties. Recent findings: Studies in different animal models have shown that monoclonal antibodies can generate long-lasting protective immunity. Induction of this vaccinal effect by HIV-1 bNAbs has also been more recently reported in animal models of HIV-1 infection. Notably, bNAbs treatment of macaques infected with the SHIV chimeric virus improved both humoral and cellular adaptive immune responses that contributed to disease control. Importantly, this concept has been extended to HIV-1 infected patients as enhancement of humoral responses was recently reported in HIV-1 patients treated with bNAbs. Studies aiming at elucidating the mechanisms underlying these immunomodulatory properties of bNAbs have identified a role for immune complexes in shaping immune responses against HIV-1. They also highlight different Fc effector functions that might be required for the enhancement of HIV-1 immune responses upon bNAbs treatment.

show abstract

Section: Mechanisms Involved In the Enhancement Of Adaptive Immune Rementioning

confidence: 53%

“…FcγRs expressed on antigen-presenting cells which in turn modulate the antiviral adaptive immune response [8][9][10]. There is now accumulating evidence that mAbs can enhance antiviral immune responses by recruiting the endogenous immune system of infected individuals.…”

Section: Introductionmentioning

confidence: 99%

Vaccinal effect of HIV-1 antibody therapy

Naranjo-Gómez¹,

Pelegrin²

2019

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

show abstract

“…A neutralizing antibody is an important factor in antiviral immunity and is also a key index to analyze the immune effect of vaccines [18]. Neutralizing antibodies kill viruses by neutralizing infectious virus particles, thus preventing viral infection and eliminating pathogens [19].…”

Section: Discussionmentioning

confidence: 99%

Acquisition and bioactivity analysis of single-chain fragment variable antibody against CSFV

Li¹,

Tao²,

Cheng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Classical swine fever (CSF) is a highly contagious disease that threatens the pig industry. Passive immunization with neutralizing antibodies against classical swine fever virus (CSFV) is an effective prevention and therapeutic measure. Results In this study, to prepare a single-chain fragment variable (scFv) antibody against CSFV, two weanling piglets were injected twice with a CSFV attenuated vaccine. After the second immunization, peripheral blood lymphocytes were separated from the blood of the piglets by lymphocyte separation medium. After FACS, B lymphocytes with FITC labelled-E2 and FITC goat anti-swine IgG were sorted, extracted and cultivated on 96-well plates for 72 h. Then, the culture supernatants of B lymphocytes were screened by indirect ELISA with the purified CSFV-E2 antigen,and the target scFv antibody was bound to CSFV and obtained. Then, the scFv gene was inserted into the eukaryotic expression plasmid pCAGGS, and the constituted plasmid pCAGGS-scFv was transfected into ST cells. Western blot analysis showed that an approximately 31 kDa fusion protein was detected in the cell supernatant. Addition, the neutralizing capacity was measured in vitro. Indirect immunofluorescence assay (IFA) results showed that scFv-16 was able to neutralize CSFV. Conclusion Our data demonstrated that scFv-16 would be an effective diagnostic tool and potential therapeutic reagent for the CSFV infection in swine.

show abstract

“…There are significant differences between the development of vaccines versus antibody-based prophylactic therapies, especially for a pathogen such as hRSV (Wang et al 2019;Villafana et al 2017;Simões et al 2018). Although the main aim of both types of treatment is to achieve a protective response against the virus, active immunization with vaccines usually results in the activation and generation of immunological memory by the adaptive immune response.…”

Section: Introductionmentioning

confidence: 99%

Antibody development for preventing the human respiratory syncytial virus pathology

Soto

Gálvez

Pacheco

et al. 2020

Mol Med

View full text Add to dashboard Cite

Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system-such as seizures, encephalopathy and encephalitis-have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies-such as the administration of antibodies-provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus-such as the G or the N hRSV proteins-have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.

show abstract

From therapeutic antibodies to immune complex vaccines

Cited by 48 publications

References 99 publications

Vaccinal effect of HIV-1 antibody therapy

Vaccinal effect of HIV-1 antibody therapy

Acquisition and bioactivity analysis of single-chain fragment variable antibody against CSFV

Antibody development for preventing the human respiratory syncytial virus pathology

Contact Info

Product

Resources

About